Activation of mononuclear cells to be used for hybrid monoclonal antibody‐induced lysis of human ovarian carcinoma cells
暂无分享,去创建一个
S. Ménard | A. Lanzavecchia | S. Canevari | D. Mezzanzanica | M. Colnaghi | M. Colnaghi | R. Fontanelli | S. Pupa | S. Pupa
[1] S. Ménard,et al. Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components , 1988, International journal of cancer.
[2] S. Ménard,et al. Anti‐ovarian carcinoma anti‐T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T‐cells , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[3] I. Barr,et al. Lysis of tumor cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies , 1987, International journal of cancer.
[4] H. Müller-Eberhard,et al. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Segal,et al. Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. , 1987, Journal of immunology.
[6] S. Ménard,et al. Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.
[7] A. Lanzavecchia,et al. The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.
[8] D. Longo,et al. Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. , 1986, Journal of immunology.
[9] H. Müller-Eberhard,et al. Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Bevan,et al. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Segal,et al. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies , 1986, The Journal of experimental medicine.
[12] S. Rosenberg. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. , 1985, Journal of the National Cancer Institute.
[13] J. da Silva,et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.
[14] J. Bluestone,et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.
[15] Osami Kanagawa,et al. Hybrid antibodies can target sites for attack by T cells , 1985, Nature.
[16] S. Ménard,et al. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. , 1983, Cancer research.
[17] G. Alles,et al. The Preparation and Purification of Pollen Extracts , 1927 .